Hydrochloric Acid → 1-(4-(7-Morpholinopyrazolo[1,5-a]pyrimidin-5-ylcarbamoyl)phenyl)cyclopropanecarboxylic acid
반응식
[O:1]1[CH2:6][CH2:5][N:4]([C:7]2[N:12]3[N:13]=[CH:14][CH:15]=[C:11]3[N:10]=[C:9]([NH:16][C:17]([C:19]3[CH:24]=[CH:23][C:22]([C:25]4([C:28]([O:30]C)=[O:29])[CH2:27][CH2:26]4)=[CH:21][CH:20]=3)=[O:18])[CH:8]=2)[CH2:3][CH2:2]1.[OH-].[Na+].Cl>CO>[O:1]1[CH2:2][CH2:3][N:4]([C:7]2[N:12]3[N:13]=[CH:14][CH:15]=[C:11]3[N:10]=[C:9]([NH:16][C:17]([C:19]3[CH:20]=[CH:21][C:22]([C:25]4([C:28]([OH:30])=[O:29])[CH2:26][CH2:27]4)=[CH:23][CH:24]=3)=[O:18])[CH:8]=2)[CH2:5][CH2:6]1참가 물질
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
Methyl 1-(4-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-ylcarbamoyl)phenyl)cyclopropanecarboxylate (Compound 441, 31 mg, 0.07 mmol) was dissolved in methanol, and 1N NaOH solution (1 ml) was then added. After 8 hours at room temperature, the mixture was acidified with 2N HCl to pH 1. The mixture was concentrated in vacuo. The residue was dissolved in DMSO, and was purified by preparatory HPLC (30-65% MeCN/H2O gradient+0.01% TFA). Lyophilization of the combined fractions gave the titled compound (6.9 mg, 23%) as a white powder. 1H NMR (400 MHz, DMSO-d6) δ=12.67-12.24 (m, 1 H), 10.98 (s, 1 H), 8.10 (d, J=2.3 Hz, 1 H), 7.98 (d, J=8.3 Hz, 2 H), 7.47 (d, J=8.3 Hz, 2 H), 7.41 (s, 1 H), 6.37 (d, J=2.3 Hz, 1 H), 3.85 (m, 2 H), 3.74 (m, 2 H), 1.56-1.45 (m, 2 H), 1.26-1.17 (m, 2 H); ESI-MS: m/z 408.4 (M+H)+.
후처리
- concentrationThe mixture was concentrated in vacuo
- dissolutionThe residue was dissolved in DMSO
- customwas purified by preparatory HPLC (30-65% MeCN/H2O gradient+0.01% TFA)
출처 및 근거
- ORD 기록
- ord-5a843f965c8b4816bfc5e2c511193796
- 출처 데이터셋
- uspto-grants-2013_06
- 특허 번호
- US08461163B2
반응 노트
불러오는 중…